ProMIS Neurosciences, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
ProMIS Neurosciences, Inc. - overview
Established
2015
Location
Toronto, ON, Canada
Primary Industry
Biotechnology
About
Based in Toronto, Canada, and founded in 2015, ProMIS Neurosciences, Inc operates as a biotechnology company that develops antibody therapeutics, targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). The company was Co-founded by Neil Cashman (CSO). In August 2023, ProMIS Neurosciences, Inc. raised USD 20.
4 million, issuing 9. 94 million shares, or USD 1. 88 apiece, in a PIPE investment, led by Affinity Asset Advisors, Ally Bridge Group, and Sphera Healthcare Us Inc. As of 2023, the company is led by its CEO Gail Farfel, and the firm trades on NASDAQ under the name of PMN.
The company provides computer modeling that predicts neurodegenerative and other misfolded protein illnesses, as well as epitopes expressed on the molecular surface of hazardous oligomers (misfolded proteins). It also creates PMN310, a monoclonal therapeutic antibody targeted to treat Alzheimer's disease (AD).
Current Investors
Sphera Fund Management, Ally Bridge Group, Affinity Asset Advisors
Primary Industry
Biotechnology
Sub Industries
Molecular Science, Genetics & Gene Therapy
Company Stage
Mature - Growth Capital
Total Amount Raised
Subscriber access only
ProMIS Neurosciences, Inc. - deals
| Deals Type | Deal Status | Target (s) | Deal Date | Investor(s) | Seller(s) | Deal size (Mn) | Enterprise value (Mn) | Post-money valuation (Mn) | EBITDA multiple (x) | Revenue multiple (x) | Lead partner (s) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| PIPE | Completed | ProMIS Neurosciences, Inc. | - | ||||||||
| PIPE | Completed | ProMIS Neurosciences, Inc. | - | ||||||||
| LP Direct, PIPE | Completed | ProMIS Neurosciences, Inc. | - |
Displaying 1 - 3 of 3
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.